The role of biomarkers in soft tissue sarcoma treatment and research

2 Views

07/18/23

Emanuela Palmerini, MD, Istituto Ortopedico Rizzoli, Bologna, Italy, outlines how biomarkers are utilized as prognostic tools in the field of soft tissue sarcomas. Unlike in the past, current knowledge of different subclasses of soft tissue sarcomas and their unique biomarkers should inform the choice between different treatment options and encourage the design of subclass-specific trials. Apps such as Sarculator can compile case-specific data to assist with this. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.